{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Number of participants who achieved CR, PR, VGPR were assessed in accordance to International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. CR: No immunofixation on serum and urine, disappearance of soft tissue plasmacytomas and \\<5% plasma cells in bone marrow. Normal serum free light chain (SFLC) ratio if disease measurable only by SFLC. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or greater than or equal to (\\>=) 90% decrease in serum M-protein with urine M-protein \\<100 milligram per 24 hours (mg/24 hrs). If disease measurable only by SFLC, \\>= 90% decrease in the difference between involved and uninvolved FLC levels (dFLC). PR: \\>= 50% reduction of serum M-protein and \\>= 90% reduction in urine M-protein or to \\<200 mg/24 hrs, or a \\>= 50% decrease in dFLC. A \\>=50% decrease in the size of soft tissue plasmacytomas present at baseline","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.","id":"OG000","title":"Cohort 1: Ixazomib 4.0 mg"},{"description":"Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in a 28-day treatment cycle for up to Cycle 62.","id":"OG001","title":"Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The response evaluable analysis set consisted of all participants who received at least one dose of ixazomib, have measurable disease at baseline, and at least one postbaseline response assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)","title":"Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"Participants"}